Clinical Trials Sponsored by Foresee Pharmaceuticals

Total 21261 results

Foresee Pharmaceuticals Co., Ltd.

Completed

Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer

Prostatic Neoplasms

Korea, Republic of, United States, Lithuania, Slovakia, Czechia
Foresee Pharmaceuticals Co., Ltd.

Completed

A Phase 1, Pharmacokinetics of the MMP-12 Inhibitor FP-025 After Multiple Oral Ascending Doses in Healthy Subjects

Healthy

Netherlands
Foresee Pharmaceuticals Co., Ltd.

Terminated

A Phase 2/3 Study to Evaluate FP-025 in Patients With Severe to Critical COVID 19

Severe to Critical COVID 19 With Associated ARDS

United States
Foresee Pharmaceuticals Co., Ltd.

Recruiting

A Dose Escalation Study of FP-045 in Patients With Fanconi Anemia

Fanconi Anemia

United States
Foresee Pharmaceuticals Co., Ltd.

Completed

The Effect of FP-025, a MMP-12 Inhibitor, on Allergen-induced Airway Responses and Airway Inflammation in Mild Eosinophilic House Dust Mite (HDM)-Allergic Asthma

Asthma, COPD

Netherlands
Foresee Pharmaceuticals Co., Ltd.

Completed

Multiple-Dose, Dose-Escalation Study to Evaluate the Safety/Tolerability and Pharmacokinetics of FP-045

Healthy Volunteers

Australia
Foresee Pharmaceuticals Co., Ltd.

Completed

Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma

Prostatic Neoplasms

Czechia, United States, Poland, Austria, Germany, Lithuania, Slovakia, Taiwan
Foresee Pharmaceuticals Co., Ltd.
InClin, Inc.

Not yet recruiting

Safety, Tolerability, and Pharmacokinetics, of Single and Multiple Ascending Doses of FP-020 in Healthy Adult Volunteers

Healthy

Australia
Foresee Pharmaceuticals Co., Ltd.
QPS-Qualitix

Completed

Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg

Prostatic Neoplasms

United States
McMaster University
Foresee Pharmaceuticals Co Inc

Recruiting

Characterizing Matrix Metalloproteinase-12 (MMP12) in Sputum

Emphysema

Canada
Foresee Pharmaceuticals Co., Ltd.
QPS-Qualitix

Completed

Phase 1 Safety, Tolerability and Pharmacokinetics (PK) Study of FP-025 in Healthy Volunteers

Healthy

Taiwan
Foresee Pharmaceuticals Co., Ltd.
QPS Holdings LLC; Changchun GeneScience Pharmaceutical Co., Ltd.

Recruiting

Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty

Puberty; Precocious, Central

United States, China, Taiwan, Puerto Rico
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation

Irritable Bowel Syndrome With Constipation | Chronic Idiopathic Constipation

United States
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain

Opioid-Induced Constipation

United States
Ironwood Pharmaceuticals, Inc.
Forest Laboratories

Completed

Trial of Linaclotide in Patients With Chronic Idiopathic Constipation

Chronic Idiopathic Constipation

United States
Ironwood Pharmaceuticals, Inc.
Forest Laboratories

Completed

Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Irritable Bowel Syndrome With Constipation

United States
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Terminated

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation (LIN-MD-63)

Irritable Bowel Syndrome With Constipation

United States, Canada
Ironwood Pharmaceuticals, Inc.
Forest Laboratories

Completed

Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Irritable Bowel Syndrome With Constipation

United States
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)

Functional Constipation in Children Ages 6-17 Years

United States, Canada
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation

Irritable Bowel Syndrome With Constipation | Chronic Constipation

United States, Canada
Forest Laboratories
Merz Pharmaceuticals GmbH

Completed

Open-label Study of Safety and Tolerability of Memantine in Children With Autism

Autism | Pediatric Autism

United States
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation

Chronic Constipation

United States, Canada
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation

Irritable Bowel Syndrome Characterized by Constipation

United States, Canada
Ironwood Pharmaceuticals, Inc.
Forest Laboratories

Completed

An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation

Irritable Bowel Syndrome With Constipation | Chronic Constipation

United States
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating

Constipation | Chronic Constipation

United States, Canada
Forest Laboratories
Merz Pharmaceuticals GmbH

Completed

Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism

Autism

United States
Ironwood Pharmaceuticals, Inc.
Forest Laboratories

Completed

Trial of Linaclotide in Patients With Chronic Constipation

Chronic Constipation

United States
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment

Postmenopausal Women With Advanced Breast Cancer

Japan
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Postmenopausal Women With Advanced Breast Cancer

Japan
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Postmenopausal Women With Advanced Breast Cancer

Japan
Novartis Pharmaceuticals
Pharmaceutical Research Associates

Withdrawn

Pharmacokinetics Study of TNO155 in Participants With Mild, Moderate, or Severe Renal Impairment Compared to Matched Healthy Participants

Renal Impairment
Novartis Pharmaceuticals
Pharmaceutical Research Associates

Withdrawn

Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants

Hepatic Impairment
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip (FACT OA2)

Osteoarthritis, Knee | Osteoarthritis, Hip

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment

Chronic HBV Infection

Hong Kong, Taiwan
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Terminated

Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee (FACT CLBP 1)

Osteoarthritis | Chronic Low Back Pain

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects

RSV Infection

United States
Melior Pharmaceuticals
Bukwang Pharmaceutical, Co., Ltd.

Completed

Adult Subjects With Uncontrolled Type 2 Diabetes

Type 2 Diabetes

United States
Tibotec Pharmaceuticals, Ireland
Tibotec Pharmaceutical Limited

Completed

A Safety Study to Evaluate the Antiviral Activity of Darunavir in Combination With Ritonavir in HIV 1 Infected Children

Human Immunodeficiency Virus 1

South Africa, Argentina, Brazil, India, Kenya
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Adults

Hepatitis C

United States
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Terminated

Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip

Osteoarthritis, Knee | Osteoarthritis, Hip

United States, Poland, United Kingdom
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects

RSV Infection

United States
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response

Hepatitis C

Belgium, United States, Puerto Rico, Netherlands
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

To Assess the Patients' Ability to Self-Administer Fasinumab (FACT DEVICE)

Osteoarthritis, Knee | Osteoarthritis, Hip

United States
Alexza Pharmaceuticals, Inc.
Pharmaceutical Research Associates

Unknown

Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder

Agitation,Psychomotor

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects

RSV Infection

United States
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV

HIV Infections | Hepatitis C

France, Spain, United States, Germany
Tibotec Pharmaceuticals, Ireland
Tibotec Pharmaceutical Limited

Completed

A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents (DIONE)

HIV-1 Infection

France, United States, Spain, Ukraine, United Kingdom, Ireland
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip (FACT LTS & OA)

Osteoarthritis of the Knee or Hip

United States, Bulgaria, Chile, Colombia, Denmark, Estonia, Germany, Hong Kong, Hungary, Italy, Lithuania, Mexico, Peru, Poland, Romania, Russian Federation, South Africa, Spain, Sweden, Ukraine, United Kingdom
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee

Osteoarthritis, Knee | Osteoarthritis, Hip

United States, Poland, United Kingdom
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip (FACT OA1)

Osteoarthritis, Knee | Osteoarthritis, Hip

United States, Poland, Hungary, Spain, Germany, United Kingdom, Denmark, Lithuania, Romania, Russian Federation, South Africa, Ukraine

Clinical Trials Sponsored by Foresee Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations